|
1
|
Miller KD, Nogueira L, Devasia T, Mariotto
AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment
and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zheng R, Zhang S, Zeng H, Wang S, Sun K,
Chen R, Li L, Wei W and He J: Cancer incidence and mortality in
China, 2016. J Natl Cancer Cent. 2:1–9. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bukowski K, Kciuk M and Kontek R:
Mechanisms of multidrug resistance in cancer chemotherapy. Int J
Mol Sci. 21:32332020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xiao X, Wang K, Zong Q, Tu Y, Dong Y and
Yuan Y: Polyprodrug with glutathione depletion and cascade drug
activation for multi-drug resistance reversal. Biomaterials.
270:1206492021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bedard PL, Hyman DM, Davids MS and Siu LL:
Small molecules, big impact: 20 Years of targeted therapy in
oncology. Lancet. 395:1078–1088. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Li M, Huang M, Lin Q, Fang Q, Liu J,
Chen X, Liu L, Zhan X, Shan H, et al: The multi-molecular
mechanisms of tumor-targeted drug resistance in precision medicine.
Biomed Pharmacother. 150:1130642022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Phan TG and Croucher PI: The dormant
cancer cell life cycle. Nat Rev Cancer. 20:398–411. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen X, Momin A, Wanggou S, Wang X, Min
HK, Dou W, Gong Z, Chan J, Dong W, Fan JJ, et al: Mechanosensitive
brain tumor cells construct blood-tumor barrier to mask
chemosensitivity. Neuron. 111:30–48. e142023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Inoue T, Aoyama-Ishikawa M, Uemura M,
Kohama K, Fujisaki N, Murakami H, Yamada T and Hirata J: The role
of death receptor signaling pathways in mouse Sertoli cell
avoidance of apoptosis during LPS- and IL-18-induced inflammatory
conditions. J Reprod Immunol. 158:1039702023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Russo M, Crisafulli G, Sogari A, Reilly
NM, Arena S, Lamba S, Bartolini A, Amodio V, Magrì A, Novara L, et
al: Adaptive mutability of colorectal cancers in response to
targeted therapies. Science. 366:1473–1480. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diaz LA Jr, Williams RT, Wu J, Kinde I,
Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al:
The molecular evolution of acquired resistance to targeted EGFR
blockade in colorectal cancers. Nature. 486:537–540. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng N, Fang J, Xue G, Wang Z, Li X, Zhou
M, Jin G, Rahman MM, McFadden G and Lu Y: Induction of tumor cell
autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome
primary and acquired resistance. Cancer Cell. 40:973–985.e7. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hirota K, Ooka M, Shimizu N, Yamada K,
Tsuda M, Ibrahim MA, Yamada S, Sasanuma H, Masutani M and Takeda S:
XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons,
olaparib and talazoparib, and a clinical alkylating agent,
temozolomide, by promoting the removal of trapped PARP1 from broken
DNA. Genes Cells. 27:331–344. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ovejero S, Soulet C and Moriel-Carretero
M: The alkylating agent Methyl methanesulfonate triggers lipid
alterations at the inner nuclear membrane that are independent from
its DNA-damaging ability. Int J Mol Sci. 22:74612021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ghosh S: Cisplatin: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fetoni AR, Paciello F and Troiani D:
Cisplatin chemotherapy and cochlear damage: Otoprotective and
chemosensitization properties of polyphenols. Antioxid Redox
Signal. 36:1229–1245. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Curry JN and McCormick JA:
Cisplatin-induced kidney injury: Delivering the goods. J Am Soc
Nephrol. 33:255–256. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Balboni B, El Hassouni B, Honeywell RJ,
Sarkisjan D, Giovannetti E, Poore J, Heaton C, Peterson C, Benaim
E, Lee YB, et al: RX-3117 (fluorocyclopentenyl cytosine): A novel
specific antimetabolite for selective cancer treatment. Expert Opin
Investig Drugs. 28:311–322. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo J, Yu Z, Das M and Huang L: Nano
codelivery of oxaliplatin and folinic acid achieves synergistic
chemo-immunotherapy with 5-fluorouracil for colorectal cancer and
liver metastasis. Acs Nano. 14:5075–5089. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Z, Li C, Wu Q, Tu Y, Wang C, Yu X, Li
B, Wang Z and Sun S and Sun S: MEDAG enhances breast cancer
progression and reduces epirubicin sensitivity through the
AKT/AMPK/mTOR pathway. Cell Death Dis. 12:972021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li J, Yu K, Pang D, Wang C, Jiang J, Yang
S, Liu Y, Fu P, Sheng Y, Zhang G, et al: Adjuvant capecitabine with
docetaxel and cyclophosphamide plus epirubicin for triple-negative
breast cancer (CBCSG010): An open-label, randomized, multicenter,
phase III trial. J Clin Oncol. 38:1774–1784. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
You JH, Lee J and Roh JL: PGRMC1-dependent
lipophagy promotes ferroptosis in paclitaxel-tolerant persister
cancer cells. J Exp Clin Cancer Res. 40:3502021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Y, Liu R, Li C, Song Y, Liu G, Huang
Q, Yu L, Zhu D, Lu C, Lu A, et al: Nab-paclitaxel promotes the
cancer-immunity cycle as a potential immunomodulator. Am J Cancer
Res. 11:3445–3460. 2021.PubMed/NCBI
|
|
25
|
Elshamy AM, Salem OM, Safa MAE, Barhoma
RAE, Eltabaa EF, Shalaby AM, Alabiad MA, Arakeeb HM and Mohamed HA:
Possible protective effects of CO Q10 against vincristine-induced
peripheral neuropathy: Targeting oxidative stress, inflammation,
and sarmoptosis. J Biochem Mol Toxicol. 36:e229762022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rajković S, Živković MD and Djuran MI:
Reactions of dinuclear Platinum(II) complexes with peptides. Curr
Protein Pept Sci. 17:95–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim ES, Tang X, Peterson DR, Kilari D,
Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II
and Siddik ZH: Copper transporter CTR1 expression and tissue
platinum concentration in non-small cell lung cancer. Lung Cancer.
85:88–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lv X, Song J, Xue K, Li Z, Li M, Zahid D,
Cao H, Wang L, Song W, Ma T, et al: Core fucosylation of copper
transporter 1 plays a crucial role in cisplatin-resistance of
epithelial ovarian cancer by regulating drug uptake. Mol Carcinog.
58:794–807. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kalayda GV, Wagner CH and Jaehde U:
Relevance of copper transporter 1 for cisplatin resistance in human
ovarian carcinoma cells. J Inorg Biochem. 116:1–10. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao H, Zhang S, Hu T, Qu X, Zhai J, Zhang
Y, Tao L, Yin J and Song Y: Omeprazole protects against
cisplatin-induced nephrotoxicity by alleviating oxidative stress,
inflammation, and transporter-mediated cisplatin accumulation in
rats and HK-2 cells. Chem Biol Interact. 297:130–140. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Naka A, Takeda R, Shintani M, Ogane N,
Kameda Y, Aoyama T, Yoshikawa T and Kamoshida S: Organic cation
transporter 2 for predicting cisplatin-based neoadjuvant
chemotherapy response in gastric cancer. Am J Cancer Res.
5:2285–2293. 2015.PubMed/NCBI
|
|
32
|
Hucke A, Rinschen MM, Bauer OB, Sperling
M, Karst U, Köppen C, Sommer K, Schröter R, Ceresa C, Chiorazzi A,
et al: An integrative approach to cisplatin chronic toxicities in
mice reveals importance of organic cation-transporter-dependent
protein networks for renoprotection. Arch Toxicol. 93:2835–2848.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Verhalen B, Dastvan R, Thangapandian S,
Peskova Y, Koteiche HA, Nakamoto RK, Tajkhorshid E and Mchaourab
HS: Energy transduction and alternating access of the mammalian ABC
transporter P-glycoprotein. Nature. 543:738–741. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alam A, Kowal J, Broude E, Roninson I and
Locher KP: Structural insight into substrate and inhibitor
discrimination by human P-glycoprotein. Science. 363:753–756. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pasello M, Giudice AM and Scotlandi K: The
ABC subfamily A transporters: Multifaceted players with incipient
potentialities in cancer. Semin Cancer Biol. 60:57–71. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hanssen KM, Haber M and Fletcher JI:
Targeting multidrug resistance-associated protein 1
(MRP1)-expressing cancers: Beyond pharmacological inhibition. Drug
Resist Updat. 59:1007952021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim Y and Chen J: Molecular structure of
human P-glycoprotein in the ATP-bound, outward-facing conformation.
Science. 359:915–919. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Miyamoto S, Azuma K, Ishii H, Bessho A,
Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, et
al: Low-dose erlotinib treatment in elderly or frail patients with
EGFR mutation-positive non-small cell lung cancer: A multicenter
phase 2 trial. JAMA Oncol. 6:e2012502020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Robey RW, Pluchino KM, Hall MD, Fojo AT,
Bates SE and Gottesman MM: Revisiting the role of ABC transporters
in multidrug-resistant cancer. Nat Rev Cancer. 18:452–464. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Carvalho DM, Richardson PJ, Olaciregui N,
Stankunaite R, Lavarino C, Molinari V, Corley EA, Smith DP, Ruddle
R, Donovan A, et al: Repurposing vandetanib plus everolimus for the
treatment of ACVR1-mutant diffuse intrinsic pontine glioma. Cancer
Discov. 12:416–431. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cole SPC: Targeting multidrug resistance
protein 1 (MRP1, ABCC1): Past, present, and future. Annu Rev
Pharmacol Toxicol. 54:95–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Johnson ZL and Chen J: ATP binding enables
substrate release from multidrug resistance protein 1. Cell.
172:81–89.e10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vulsteke C, Lambrechts D, Dieudonné A,
Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski
P, Paridaens R and Wildiers H: Genetic variability in the multidrug
resistance associated protein-1 (ABCC1/MRP1) predicts hematological
toxicity in breast cancer patients receiving (neo-)adjuvant
chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide
(FEC). Ann Oncol. 24:1513–1525. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cole SPC: Multidrug resistance protein 1
(MRP1, ABCC1), a ‘multitasking’ ATP-binding cassette (ABC)
transporter. J Biol Chem. 289:30880–30888. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Taylor NMI, Manolaridis I, Jackson SM,
Kowal J, Stahlberg H and Locher KP: Structure of the human
multidrug transporter ABCG2. Nature. 546:504–509. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kowal J, Ni D, Jackson SM, Manolaridis I,
Stahlberg H and Locher KP: Structural basis of drug recognition by
the multidrug transporter ABCG2. J Mol Biol. 433:1669802021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Niu B, Liao K, Zhou Y, Wen T, Quan G, Pan
X and Wu C: Application of glutathione depletion in cancer therapy:
Enhanced ROS-based therapy, ferroptosis, and chemotherapy.
Biomaterials. 277:1211102021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang J, Bai J, Zhou Q, Hu Y, Wang Q, Yang
L, Chen H, An H, Zhou C, Wang Y, et al: Glutathione prevents high
glucose-induced pancreatic fibrosis by suppressing pancreatic
stellate cell activation via the ROS/TGFβ/SMAD pathway. Cell Death
Dis. 13:4402022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen M, Zhao S, Zhu J, Feng E, Lv F, Chen
W, Lv S, Wu Y, Peng X and Song F: Open-source and
reduced-expenditure nanosystem with ROS self-amplification and
glutathione depletion for simultaneous augmented
chemodynamic/photodynamic therapy. ACS Appl Mater Interfaces.
14:20682–20692. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cheng X, Xu HD, Ran HH, Liang G and Wu FG:
Glutathione-depleting nanomedicines for synergistic cancer therapy.
ACS Nano. 15:8039–8068. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gao P, Yang X, Xue YW, Zhang XF, Wang Y,
Liu WJ and Wu XJ: Promoter methylation of glutathione S-transferase
pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma
and its correlation with DNA methyltransferase 1 expression.
Cancer. 115:3222–3232. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xu Y, Han X, Li Y, Min H, Zhao X, Zhang Y,
Qi Y, Shi J, Qi S, Bao Y and Nie G: Sulforaphane mediates
glutathione depletion via polymeric nanoparticles to restore
cisplatin chemosensitivity. ACS Nano. 13:13445–13455. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Oshimori N, Oristian D and Fuchs E: TGF-β
promotes heterogeneity and drug resistance in squamous cell
carcinoma. Cell. 160:963–976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang KR, Zhang YF, Lei HM, Tang YB, Ma
CS, Lv QM, Wang SY, Lu LM, Shen Y, Chen HZ and Zhu L: Targeting
AKR1B1 inhibits glutathione de novo synthesis to overcome acquired
resistance to EGFR-targeted therapy in lung cancer. Sci Transl Med.
13:eabg64282021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pang HH, Ke YC, Li NS, Chen YT, Huang CY,
Wei KC and Yang HW: A new lateral flow plasmonic biosensor based on
gold-viral biomineralized nanozyme for on-site intracellular
glutathione detection to evaluate drug-resistance level. Biosens
Bioelectron. 165:1123252020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Harris IS, Endress JE, Coloff JL, Selfors
LM, McBrayer SK, Rosenbluth JM, Takahashi N, Dhakal S, Koduri V,
Oser MG, et al: Deubiquitinases maintain protein homeostasis and
survival of cancer cells upon glutathione depletion. Cell Metab.
29:1166–1181.e6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Stafford WC, Peng X, Olofsson MH, Zhang X,
Luci DK, Lu L, Cheng Q, Trésaugues L, Dexheimer TS, Coussens NP, et
al: Irreversible inhibition of cytosolic thioredoxin reductase 1 as
a mechanistic basis for anticancer therapy. Sci Transl Med.
10:eaaf74442018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang X, Wang M, Feng J, Qin B, Zhang C,
Zhu C, Liu W, Wang Y, Liu W, Huang L, et al: Multifunctional
nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs
for treatment of chemotherapy-resistant esophageal cancer. J
Nanobiotechnology. 20:1662022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Amort M, Nachbauer B, Tuzlak S, Kieser A,
Schepers A, Villunger A and Polacek N: Expression of the vault RNA
protects cells from undergoing apoptosis. Nat Commun. 6:70302015.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu S, Hao Q, Peng N, Yue X, Wang Y, Chen
Y, Wu J and Zhu Y: Major vault protein: A virus-induced host factor
against viral replication through the induction of type-I
interferon. Hepatology. 56:57–66. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bai H, Wang C, Qi Y, Xu J, Li N, Chen L,
Jiang B, Zhu X, Zhang H, Li X, et al: Major vault protein
suppresses lung cancer cell proliferation by inhibiting STAT3
signaling pathway. BMC Cancer. 19:4542019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shen W, Qiu Y, Li J, Wu C, Liu Z, Zhang X,
Hu X, Liao Y and Wang H: IL-25 promotes cisplatin resistance of
lung cancer cells by activating NF-κB signaling pathway to increase
of major vault protein. Cancer Med. 8:3491–3501. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lou L, Wang J, Lv F, Wang G, Li Y, Xing L,
Shen H and Zhang X: Y-box binding protein 1 (YB-1) promotes
gefitinib resistance in lung adenocarcinoma cells by activating AKT
signaling and epithelial-mesenchymal transition through targeting
major vault protein (MVP). Cell Oncol (Dordr). 44:109–133. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yu X, Liu W, Wang Z, Wang H, Liu J, Huang
C, Zhao T, Wang X, Gao S, Ma Y, et al: CD73 induces gemcitabine
resistance in pancreatic ductal adenocarcinoma: A promising target
with non-canonical mechanisms. Cancer Lett. 519:289–303. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yu H, Li M, He R, Fang P, Wang Q, Yi Y,
Wang F, Zhou L, Zhang Y, Chen A, et al: Major vault protein
promotes hepatocellular carcinoma through targeting interferon
regulatory factor 2 and decreasing p53 activity. Hepatology.
72:518–534. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Pilié PG, Tang C, Mills GB and Yap TA:
State-of-the-art strategies for targeting the DNA damage response
in cancer. Nat Rev Clin Oncol. 16:81–104. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gourley C, Balmaña J, Ledermann JA, Serra
V, Dent R, Loibl S, Pujade-Lauraine E and Boulton SJ: Moving from
poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and
DNA damage response in cancer therapy. J Clin Oncol. 37:2257–2269.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Pettitt SJ, Frankum JR, Punta M, Lise S,
Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ and Lord CJ:
Clinical BRCA1/2 reversion analysis identifies hotspot mutations
and predicted neoantigens associated with therapy resistance.
Cancer Discov. 10:1475–1488. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ma J, Benitez JA, Li J, Miki S, Ponte de
Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, et
al: Inhibition of nuclear PTEN tyrosine phosphorylation enhances
glioma radiation sensitivity through attenuated DNA repair. Cancer
Cell. 35:504–518.e7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Goodall J, Mateo J, Yuan W, Mossop H,
Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu
S, et al: Circulating cell-free DNA to guide prostate cancer
treatment with PARP inhibition. Cancer Discov. 7:1006–1017. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Dev H, Chiang TW, Lescale C, de Krijger I,
Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W,
Ostermaier M, et al: Shieldin complex promotes DNA end-joining and
counters homologous recombination in BRCA1-null cells. Nat Cell
Biol. 20:954–965. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Schlacher K: PARPi focus the spotlight on
replication fork protection in cancer. Nat Cell Biol. 19:1309–1310.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lord CJ and Ashworth A: Mechanisms of
resistance to therapies targeting BRCA-mutant cancers. Nat Med.
19:1381–1388. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ray Chaudhuri A, Callen E, Ding X, Gogola
E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, et
al: Replication fork stability confers chemoresistance in
BRCA-deficient cells. Nature. 535:382–387. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Awah CU, Chen L, Bansal M, Mahajan A,
Winter J, Lad M, Warnke L, Gonzalez-Buendia E, Park C, Zhang D, et
al: Ribosomal protein S11 influences glioma response to TOP2
poisons. Oncogene. 39:5068–5081. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wang Z, Zhu Q, Li X, Ren X, Li J, Zhang Y,
Zeng S, Xu L, Dong X and Zhai B: TOP2A inhibition reverses drug
resistance of hepatocellular carcinoma to regorafenib. Am J Cancer
Res. 12:4343–4360. 2022.PubMed/NCBI
|
|
78
|
Mateo J, Carreira S, Sandhu S, Miranda S,
Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A,
Tunariu N, et al: DNA-repair defects and olaparib in metastatic
prostate cancer. N Engl J Med. 373:1697–1708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Mu Y, Lou J, Srivastava M, Zhao B, Feng
XH, Liu T, Chen J and Huang J: SLFN11 inhibits checkpoint
maintenance and homologous recombination repair. EMBO Rep.
17:94–109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gardner EE, Lok BH, Schneeberger VE,
Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E,
Nguyen T, et al: Chemosensitive relapse in small cell lung cancer
proceeds through an EZH2-SLFN11 axis. Cancer Cell. 31:286–299.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Guryanova OA, Shank K, Spitzer B, Luciani
L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A,
Hoermann G, et al: DNMT3A mutations promote anthracycline
resistance in acute myeloid leukemia via impaired nucleosome
remodeling. Nat Med. 22:1488–1495. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Picco G, Cattaneo CM, van Vliet EJ,
Crisafulli G, Rospo G, Consonni S, Vieira SF, Rodríguez IS,
Cancelliere C, Banerjee R, et al: Werner helicase is a
synthetic-lethal vulnerability in mismatch repair-deficient
colorectal cancer refractory to targeted therapies, chemotherapy,
and immunotherapy. Cancer Discov. 11:1923–1937. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Germano G, Lamba S, Rospo G, Barault L,
Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, et
al: Inactivation of DNA repair triggers neoantigen generation and
impairs tumour growth. Nature. 552:116–120. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Gay CM, Parseghian CM and Byers LA: This
is our cells under pressure: Decreased DNA damage repair in
response to targeted therapies facilitates the emergence of
drug-resistant clones. Cancer Cell. 37:5–7. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Guo W, Qiao T, Dong B, Li T, Liu Q and Xu
X: The effect of hypoxia-induced exosomes on anti-tumor immunity
and its implication for immunotherapy. Front Immunol.
13:9159852022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Qin Y, Liu HJ, Li M, Zhai DH, Tang YH,
Yang L, Qiao KL, Yang JH, Zhong WL, Zhang Q, et al: Salidroside
improves the hypoxic tumor microenvironment and reverses the drug
resistance of platinum drugs via HIF-1α signaling pathway.
EBioMedicine. 38:25–36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wu S, Luo M, To KKW, Zhang J, Su C, Zhang
H, An S, Wang F, Chen D and Fu L: Intercellular transfer of
exosomal wild type EGFR triggers osimertinib resistance in
non-small cell lung cancer. Mol Cancer. 20:172021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Carter BZ, Mak PY, Chen Y, Mak DH, Mu H,
Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, et al:
Anti-apoptotic ARC protein confers chemoresistance by controlling
leukemia-microenvironment interactions through a NFκB/IL1β
signaling network. Oncotarget. 7:20054–20067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Carter BZ, Mak PY, Wang X, Tao W, Ruvolo
V, Mak D, Mu H, Burks JK and Andreeff M: An ARC-regulated
IL1β/Cox-2/PGE2/β-catenin/ARC circuit controls
leukemia-microenvironment interactions and confers drug resistance
in AML. Cancer Res. 79:1165–1177. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chambers LM, Esakov Rhoades EL, Bharti R,
Braley C, Tewari S, Trestan L, Alali Z, Bayik D, Lathia JD, Sangwan
N, et al: Disruption of the gut microbiota confers cisplatin
resistance in epithelial ovarian cancer. Cancer Res. 82:4654–4669.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Johnston CD and Bullman S:
Bacteria-derived L-lactate fuels cervical cancer chemoradiotherapy
resistance. Trends Cancer. 10:97–99. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Jiang SS, Xie YL, Xiao XY, Kang ZR, Lin
XL, Zhang L, Li CS, Qian Y, Xu PP, Leng XX, et al: Fusobacterium
nucleatum-derived succinic acid induces tumor resistance to
immunotherapy in colorectal cancer. Cell Host Microbe.
31:781–797.e9. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Lin ZZ, Hu MC, Hsu C, Wu YM, Lu YS, Ho JA,
Yeh SH, Chen PJ and Cheng AL: Synergistic efficacy of
telomerase-specific oncolytic adenoviral therapy and histone
deacetylase inhibition in human hepatocellular carcinoma. Cancer
Lett. 556:2160632023. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Vaidya FU, Sufiyan Chhipa A, Mishra V,
Gupta VK, Rawat SG, Kumar A and Pathak C: Molecular and cellular
paradigms of multidrug resistance in cancer. Cancer Rep (Hoboken).
5:e12912022. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Freter R, Falletta P, Omrani O, Rasa M,
Herbert K, Annunziata F, Minetti A, Krepelova A, Adam L, Käppel S,
et al: Establishment of a fluorescent reporter of RNA-polymerase II
activity to identify dormant cells. Nat Commun. 12:33182021.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Summers MA, McDonald MM and Croucher PI:
Cancer cell dormancy in metastasis. Cold Spring Harb Perspect Med.
10:a0375562020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yeh AC and Ramaswamy S: Mechanisms of
cancer cell dormancy-another hallmark of cancer? Cancer Res.
75:5014–5022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Pajic M, Blatter S, Guyader C, Gonggrijp
M, Kersbergen A, Küçükosmanoğlu A, Sol W, Drost R, Jonkers J, Borst
P and Rottenberg S: Selected alkylating agents can overcome drug
tolerance of G0-like tumor cells and eradicate
BRCA1-deficient mammary tumors in mice. Clin Cancer Res.
23:7020–7033. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Badia-Ramentol J, Linares J, Gómez-Llonin
A and Calon A: Minimal residual disease, metastasis and immunity.
Biomolecules. 11:1302021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Rehman SK, Haynes J, Collignon E, Brown
KR, Wang Y, Nixon AML, Bruce JP, Wintersinger JA, Singh Mer A, Lo
EBL, et al: Colorectal cancer cells enter a diapause-like DTP state
to survive chemotherapy. Cell. 184:226–242.e21. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Cackowski FC and Heath EI: Prostate cancer
dormancy and recurrence. Cancer Lett. 524:103–108. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Akkoc Y, Peker N, Akcay A and Gozuacik D:
Autophagy and cancer dormancy. Front Oncol. 11:6270232021.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Damen MPF, van Rheenen J and Scheele CLGJ:
Targeting dormant tumor cells to prevent cancer recurrence. FEBS J.
288:6286–6303. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Lee J, Kim SH and Kang BJ: Prognostic
factors of disease recurrence in breast cancer using quantitative
and qualitative magnetic resonance imaging (MRI) parameters. Sci
Rep. 10:75982020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Hampsch RA, Wells JD, Traphagen NA,
McCleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD,
Demidenko E, et al: AMPK activation by metformin promotes survival
of dormant ER+ breast cancer cells. Clin Cancer Res.
26:3707–3719. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhu X, Wang F, Wu X, Li Z, Wang Z, Ren X,
Zhou Y, Song F, Liang Y, Zeng Z, et al: FBX8 promotes metastatic
dormancy of colorectal cancer in liver. Cell Death Dis. 11:6222020.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Quayle LA, Spicer A, Ottewell PD and Holen
I: Transcriptomic profiling reveals novel candidate genes and
signalling programs in breast cancer quiescence and dormancy.
Cancers (Basel). 13:39222021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Preciado J, Lam T, Azarin SM, Lou E and
Aksan A: Induction of dormancy by confinement: An agarose-silica
biomaterial for isolating and analyzing dormant cancer cells. J
Biomed Mater Res B Appl Biomater. 109:2117–2130. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Drescher F, Juárez P, Arellano DL,
Serafín-Higuera N, Olvera-Rodriguez F, Jiménez S, Licea-Navarro AF
and Fournier PG: TIE2 induces breast cancer cell dormancy and
inhibits the development of osteolytic bone metastases. Cancers
(Basel). 12:8682020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Cho J, Min HY, Lee HJ, Hyun SY, Sim JY,
Noh M, Hwang SJ, Park SH, Boo HJ, Lee HJ, et al: RGS2-mediated
translational control mediates cancer cell dormancy and tumor
relapse. J Clin Invest. 131:e1719012021. View Article : Google Scholar
|
|
111
|
Clark AM, Heusey HL, Griffith LG,
Lauffenburger DA and Wells A: IP-10 (CXCL10) can trigger emergence
of dormant breast cancer cells in a metastatic liver
microenvironment. Front Oncol. 11:6761352021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Yu Z, Zhou R, Zhao Y, Pan Y, Liang H,
Zhang JS, Tai S, Jin L and Teng CB: Blockage of SLC31A1-dependent
copper absorption increases pancreatic cancer cell autophagy to
resist cell death. Cell Prolif. 52:e125682019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Tsvetkov P, Coy S, Petrova B, Dreishpoon
M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R,
Spangler RD, et al: Copper induces cell death by targeting
lipoylated TCA cycle proteins. Science. 375:1254–1261. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Kurppa KJ, Liu Y, To C, Zhang T, Fan M,
Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, et al:
Treatment-induced tumor dormancy through YAP-mediated
transcriptional reprogramming of the apoptotic pathway. Cancer
Cell. 37:104–122.e12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Dhimolea E, de Matos Simoes R, Kansara D,
Al'Khafaji A, Bouyssou J, Weng X, Sharma S, Raja J, Awate P,
Shirasaki R, et al: An embryonic diapause-like adaptation with
suppressed Myc activity enables tumor treatment persistence. Cancer
Cell. 39:240–256.e11. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Hussein AM, Wang Y, Mathieu J, Margaretha
L, Song C, Jones DC, Cavanaugh C, Miklas JW, Mahen E, Showalter MR,
et al: Metabolic control over mTOR-dependent diapause-like state.
Dev Cell. 52:236–250. e72020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare
S, Kondo S, Kondo Y, Yu Y, Mills GB, et al: The tumor suppressor
gene ARHI regulates autophagy and tumor dormancy in human ovarian
cancer cells. J Clin Invest. 118:3917–3929. 2008.PubMed/NCBI
|
|
118
|
Anlaş AA and Nelson CM: Soft
microenvironments induce chemoresistance by increasing autophagy
downstream of integrin-linked kinase. Cancer Res. 80:4103–4113.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Tallón de Lara P, Castañón H, Vermeer M,
Núñez N, Silina K, Sobottka B, Urdinez J, Cecconi V, Yagita H,
Movahedian Attar F, et al:
CD39+PD-1+CD8+ T cells mediate
metastatic dormancy in breast cancer. Nat Commun. 12:7692021.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Ju S, Wang F, Wang Y and Ju S: CSN8 is a
key regulator in hypoxia-induced epithelial-mesenchymal transition
and dormancy of colorectal cancer cells. Mol Cancer. 19:1682020.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Chen ML, Sun A, Cao W, Eliason A, Mendez
KM, Getzler AJ, Tsuda S, Diao H, Mukori C, Bruno NE, et al:
Physiological expression and function of the MDR1 transporter in
cytotoxic T lymphocytes. J Exp Med. 217:e201913882020. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Mu QG, Lin G, Jeon M, Wang H, Chang FC,
Revia RA, Yu J and Zhang M: Iron oxide nanoparticle targeted
chemo-immunotherapy for triple negative breast cancer. Mater Today
(Kidlington). 50:149–169. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Li S, Li C, Jin S, Liu J, Xue X, Eltahan
AS, Sun J, Tan J, Dong J and Liang XJ: Overcoming resistance to
cisplatin by inhibition of glutathione S-transferases (GSTs) with
ethacraplatin micelles in vitro and in vivo. Biomaterials.
144:119–129. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Ling X, Chen X, Riddell IA, Tao W, Wang J,
Hollett G, Lippard SJ, Farokhzad OC, Shi J and Wu J:
Glutathione-scavenging poly(disulfide amide) nanoparticles for the
effective delivery of Pt(IV) prodrugs and reversal of cisplatin
resistance. Nano Lett. 18:4618–4625. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wu F, Du Y, Yang J, Shao B, Mi Z, Yao Y,
Cui Y, He F, Zhang Y and Yang P: Peroxidase-like active
nanomedicine with dual glutathione depletion property to restore
oxaliplatin chemosensitivity and promote programmed cell death. ACS
Nano. 16:3647–3663. 2022. View Article : Google Scholar : PubMed/NCBI
|
